SCHEMBL6185153

SCHEMBL6185153

COC(=O)[C@@H]1C=C(c2ccc(C(F)(F)F)cc2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
NR1H2 P55055 2/20 0.40
NR1H3 Q13133 1/20 0.40
POLB P06746 1/20 0.38
PTPN1 P18031 1/20 0.38
MMP13 P45452 1/20 0.37
GHSR Q92847 1/20 0.37
CCNT1 O60563 2/20 0.37
CDK9 P50750 2/20 0.37
GPR119 Q8TDV5 1/20 0.36
P2RY14 Q15391 1/20 0.36
CYP3A4 P08684 2/20 0.36
MAPK1 P28482 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23632405 1.00 MAPT (0.42) MAPTNR1H2NR1H3POLBPTPN1
SCHEMBL16972131 0.87 ESR2 (0.40) NR1H2NR1H3PTPN1CCNT1CDK9
SCHEMBL16972132 0.87 ESR2 (0.40) NR1H2NR1H3PTPN1CCNT1CDK9
SCHEMBL28842109 0.86 USP30 (0.42) NR1H2NR1H3PTPN1MMP13CCNT1
SCHEMBL16972092 0.86 UCHL1 (0.41) NR1H2NR1H3PTPN1CCNT1CDK9
SCHEMBL16972090 0.86 UCHL1 (0.41) NR1H2NR1H3PTPN1CCNT1CDK9
SCHEMBL23632067 0.81 NR1H2 (0.42) MAPTNR1H2NR1H3MMP13GHSR
SCHEMBL23631967 0.81 NR1H2 (0.42) MAPTNR1H2NR1H3MMP13GHSR
SCHEMBL3652108 0.79 PTPN1 (0.40) MAPTNR1H2NR1H3POLBPTPN1
SCHEMBL3652106 0.79 PTPN1 (0.40) MAPTNR1H2NR1H3POLBPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF MAZE THERAPEUTICS INC (US) 2025-10-16 US disclosed
US-20230121086-A1 RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-04-20 US disclosed
EP-4089080-A1 RORyT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2022-11-16 EP disclosed
WO-2021139595-A1 RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 东莞市东阳光新药研发有限公司 2021-07-15 WO disclosed
CN-113072542-A ROR gamma t inhibitor and preparation method and application thereof 广东东阳光药业有限公司 2021-07-06 CN disclosed
CN-112513021-A ROR gamma antagonist and application thereof in medicine 广东东阳光药业有限公司 2021-03-16 CN disclosed
US-20050256166-A1 Nitrogen-containing compounds ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1535906-A1 NITROGEN-CONTAINING COMPOUNDS ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256166-A1 Nitrogen-containing compounds DPP4, DPP3, DPP8 MAPT 2743/4885NR1H2 3917/4885NR1H3 4287/4885
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF APOL1, APOB, LDLR MAPT 431/4885NR1H2 16/4885NR1H3 20/4885
US-20230121086-A1 RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF RORC, RORB, RORA MAPT 1063/4885NR1H2 5/4885NR1H3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.